Latest News
Roche Backs Lean Mass Preservation With $2.3bn Hanmi Obesity Deal
Roche has placed a fresh bet on lean mass preservation, the most contested new frontier in obesity drug development. On 24 August 2026, its Genentech unit licensed an experimental candidate from South Korea’s Hanmi Pharmaceutical. The drug, HM17321, is designed to...
Latest News
How Sustainability Can Become a Competitive Advantage in Biomanufacturing
Sustainability has become an expectation across the life sciences industry. Regulations are evolving, customers expect more from suppliers, and companies are making increasingly ambitious environmental commitments. Compliance has helped create a common baseline for...
Obesity Drug News: GLP-1 Readouts and Approval Watch
This page is the running record of obesity drug news at Life Science Daily News. It tracks what moved in the obesity and GLP-1 pipeline each month. Entries cover trial readouts, regulatory filings, approvals and label expansions. New entries are added monthly, with...
Creative Biolabs’ CAR Engineering: Moving Cell Programming Inside the Body
CAR cell therapy has demonstrated that immune cells can be genetically programmed to recognize and attack disease-associated targets. Yet conventional CAR-T therapy generally depends on an elaborate ex vivo workflow involving cell collection, genetic modification,...
Genglycos Gene Therapy Approval Sets New Bar for Rare Metabolic Disease
The Genglycos gene therapy approval gives patients with glycogen storage disease type Ia a new option. The FDA describes it as the first approved treatment for the condition. It is designed to address the underlying cause. The US Food and Drug Administration granted...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
AI-Discovered Drugs in 2026: The State of Play
Rentosertib reaches Phase III, Isomorphic Labs raises $2.1 billion, and the EU defers its high-risk AI deadlines. What is still missing for AI-discovered drugs is an approval. AI-discovered drugs entered a different phase in 2026. One molecule has now reached a Phase...
Why Ingredient Research Is Only the Beginning of a Health Product
I spent years formulating low-carbohydrate, low-calorie, high-protein and gluten-free foods. That work taught me a lesson that is easy to miss when a new ingredient has exciting research behind it: an ingredient is not a finished product. A study can tell you that an...
Weekly News Roundup | 24 August 2026
Life science news 24 August 2026: the FDA clears Regeneron’s Pasatru for an ultra-rare bone disorder and grants Ultragenyx the first gene therapy for glycogen storage disease type Ia, authorises the first standalone robotic blood-draw device, and the MHRA opens a...
The Role of Ambient AI in the Future of Specialty Care
For over a decade, the administrative burden in specialty medicine has quietly worsened. Orthopedic surgeons doing 40 patients a day are spending more time in the EHR than in the room. Ambient AI scribes have changed that equation in ways that are only beginning to...
Intismeran Autogene Phase 3 Win Moves Cancer Vaccines to Logistics
Merck and Moderna have reported what they describe as the first positive Phase 3 result for an individualised cancer therapy. Intismeran autogene, given with pembrolizumab, met its primary endpoint in resected melanoma. The companies announced the outcome on 19 August...
APAC Biopharma in 2026: Asia’s Shift From Supplier to Source
APAC biopharma has stopped being a cost line in somebody else’s budget. For two decades the region supplied ingredients, capacity and inexpensive trial sites. The companies that used them were headquartered elsewhere. That relationship has now inverted. The clearest...
Beyond the Benchmark: A Four-Layer Framework for Evaluating Healthcare AI
Healthcare AI is often evaluated where it is easiest to measure: on a dataset. Accuracy, sensitivity, specificity, calibration, retrieval quality, hallucination rates and task-completion scores all matter. But they answer only the first question: can the model perform...
The Next Era of Cardiorenal Care Is Precision Fluid Management
Medicine has become increasingly specialized over the past several decades, driving tremendous advances in our ability to diagnose and treat complex diseases. Specialists now possess deeper expertise than ever before, allowing clinicians to deliver highly targeted...
Clinical Trials Roundup | 21 Aug 2026
Merck and Moderna’s intismeran autogene meets its primary endpoint in the Phase 3 INTerpath-001 trial in completely resected melanoma, Ultragenyx’s Genglycos receives FDA accelerated approval as the first treatment for glycogen storage disease type Ia, argenx’s...
The Ketogenic Diet: Why Long-Term Safety Deserves Greater Scrutiny
The ketogenic diet has transitioned from a highly specialized therapeutic intervention to a widely promoted dietary strategy for weight loss, metabolic health, inflammation, and, in some circles, cancer prevention or treatment. Its popularity has outpaced the strength...
Human-in-the-Loop or Human-on-the-Loop? Pharma’s AI Authority Test
“But what can this AI model actually do?” It’s a common question being asked across the life sciences industry. Can it classify a symptom, summarize a trial record, predict a molecule’s behavior, or monitor a manufacturing process? Those capabilities matter, but they...
Physical Activity and Dementia: The Evidence Base Is Uneven
The link between physical activity and dementia depends on where that activity happens, according to a meta analysis of 74 studies covering more than four million adults. Leisure time exercise was associated with a lower risk of dementia, while activity undertaken at...
AI-Discovered Drugs in 2026: The State of Play
Rentosertib reaches Phase III, Isomorphic Labs raises $2.1 billion, and the EU defers its high-risk AI deadlines. What is still missing for AI-discovered drugs is an approval. AI-discovered drugs entered a different phase in 2026. One molecule has now reached a Phase...
Why Ingredient Research Is Only the Beginning of a Health Product
I spent years formulating low-carbohydrate, low-calorie, high-protein and gluten-free foods. That work taught me a lesson that is easy to miss when a new ingredient has exciting research behind it: an ingredient is not a finished product. A study can tell you that an...
Weekly News Roundup | 24 August 2026
Life science news 24 August 2026: the FDA clears Regeneron’s Pasatru for an ultra-rare bone disorder and grants Ultragenyx the first gene therapy for glycogen storage disease type Ia, authorises the first standalone robotic blood-draw device, and the MHRA opens a...
The Role of Ambient AI in the Future of Specialty Care
For over a decade, the administrative burden in specialty medicine has quietly worsened. Orthopedic surgeons doing 40 patients a day are spending more time in the EHR than in the room. Ambient AI scribes have changed that equation in ways that are only beginning to...
Intismeran Autogene Phase 3 Win Moves Cancer Vaccines to Logistics
Merck and Moderna have reported what they describe as the first positive Phase 3 result for an individualised cancer therapy. Intismeran autogene, given with pembrolizumab, met its primary endpoint in resected melanoma. The companies announced the outcome on 19 August...
APAC Biopharma in 2026: Asia’s Shift From Supplier to Source
APAC biopharma has stopped being a cost line in somebody else’s budget. For two decades the region supplied ingredients, capacity and inexpensive trial sites. The companies that used them were headquartered elsewhere. That relationship has now inverted. The clearest...
Beyond the Benchmark: A Four-Layer Framework for Evaluating Healthcare AI
Healthcare AI is often evaluated where it is easiest to measure: on a dataset. Accuracy, sensitivity, specificity, calibration, retrieval quality, hallucination rates and task-completion scores all matter. But they answer only the first question: can the model perform...
The Next Era of Cardiorenal Care Is Precision Fluid Management
Medicine has become increasingly specialized over the past several decades, driving tremendous advances in our ability to diagnose and treat complex diseases. Specialists now possess deeper expertise than ever before, allowing clinicians to deliver highly targeted...
Clinical Trials Roundup | 21 Aug 2026
Merck and Moderna’s intismeran autogene meets its primary endpoint in the Phase 3 INTerpath-001 trial in completely resected melanoma, Ultragenyx’s Genglycos receives FDA accelerated approval as the first treatment for glycogen storage disease type Ia, argenx’s...
The Ketogenic Diet: Why Long-Term Safety Deserves Greater Scrutiny
The ketogenic diet has transitioned from a highly specialized therapeutic intervention to a widely promoted dietary strategy for weight loss, metabolic health, inflammation, and, in some circles, cancer prevention or treatment. Its popularity has outpaced the strength...
Human-in-the-Loop or Human-on-the-Loop? Pharma’s AI Authority Test
“But what can this AI model actually do?” It’s a common question being asked across the life sciences industry. Can it classify a symptom, summarize a trial record, predict a molecule’s behavior, or monitor a manufacturing process? Those capabilities matter, but they...
Physical Activity and Dementia: The Evidence Base Is Uneven
The link between physical activity and dementia depends on where that activity happens, according to a meta analysis of 74 studies covering more than four million adults. Leisure time exercise was associated with a lower risk of dementia, while activity undertaken at...
Featured Articles
Further News
The Next Recruitment Challenge Isn’t Awareness, It’s Qualification
For years, the clinical research industry has focused heavily on one question: How do we reach more patients? Digital advertising, social media campaigns, patient advocacy partnerships, and online recruitment platforms have dramatically expanded researchers' ability...
From Digital Transformation to Operational Intelligence in Healthcare
Healthcare has never really had a technology problem. The greater challenge has been turning technology into better ways of working. Over the past decade, healthcare organizations have invested heavily in electronic health records, digital services, automation,...
Fatty Pancreas Disorder and the New Era of Integrated Obesity Management
Obesity is increasingly recognized as a chronic systemic disease characterized not only by excess adiposity but also by progressive dysfunction of multiple organs. Recent advances have shifted attention from body weight alone toward ectopic fat deposition as a major...
Rethinking Biomedical Research in the Age of AI
The paradox of modern biomedical research Biomedical research has never generated so much knowledge, and researchers have never struggled so much to keep pace with it. PubMed now indexes more than 40 million references drawn from roughly 26,000 journals[1]....
Australia Marks 40 years of Daffodil Day on Thursday 20 August
Cancer Council calls on Australians to help fund the next 40 years of breakthroughs One of Australia's most iconic and enduring fundraising campaigns, Daffodil Day, will return on Thursday 20 August 2026, marking 40 years of Australians coming together to support...
Retatrutide Black Market: Lilly Sues Six US Sellers
Eli Lilly has filed six lawsuits against United States companies. It accuses them of selling illegal versions of its experimental obesity drug, which remains in Phase 3 trials. The retatrutide black market runs through peptide websites, medical spas and wellness...
Modeling T Cell Dysfunction: New Frontiers in Immunometabolism
While cancer immunotherapies—particularly immune checkpoint blockades (ICBs)—have transformed clinical oncology, primary and acquired resistance remain major hurdles in solid tumors. Mounting evidence reveals that this non-responsiveness is deeply tied to the...
Beyond Tolvaptan: The Next Generation of ADPKD Therapies
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and the leading monogenic cause of kidney failure worldwide, affecting an estimated 12.5 million people globally. For nearly a decade, tolvaptan — a vasopressin V2...
What Trauma Taught Me That Medical School Never Did
Medical school taught me how to diagnose disease, interpret imaging, manage pain, and treat injury. It taught me remarkably little about what chronic trauma does to the body. Like many physicians, I was trained to think of trauma primarily as a psychological injury,...
CAR-T Therapy Explained: A Plain-English Guide
CAR-T therapy is one of the most discussed cancer treatments of the past decade, and one of the most widely misunderstood. The name is an acronym. The science involves genetic engineering. The price runs to hundreds of thousands of pounds per patient. This guide...
Beyond Detection: What Our Microplastics Study Means for Clinical Practice
For years, the conversation around microplastics centered on a simple question: Are they present in the human body? The answer is now increasingly clear. Microplastics have been detected in human blood, placentas, lungs, liver tissue, arterial plaque, reproductive...
Weekly News Roundup | 17 August 2026
Life science news 17 August 2026: Donald Trump signs an executive order seeking to narrow the US childhood vaccine schedule, the MHRA makes the UK the first country in Europe to authorise Eli Lilly’s orforglipron tablet, and Jazz Pharmaceuticals pays $820 million...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.